By Doug Macron

Santaris Pharma this week asked a US District Court to dismiss a patent-infringement lawsuit filed against it by Isis Pharmaceuticals, arguing that its research and development activities at issue in the case occur outside of the US and therefore are not subject to the nation's patent laws.

Even if they did occur in the US, Santaris argued, such activities would be protected by a statutory patent exemption and therefore no infringement would have occurred.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Nature has retracted a 2002 epigenetics paper for image manipulation.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.